The group's principle activity is to provide advanced molecular support for difficult oncology cases. The group’s PathFinderTG(R) is a patented advanced testing platform for resolving indeterminate, atypical, suspicious, equivocal and non-diagnostic specimen diagnoses from the original pathology specimen. The group operates from United States.
